Back

The early metabolic cardiac targets of Empagliflozin during the development of heart failure, independent of SGLT2 inhibition

26 January 2026 (17:30 - 17:40)
Organised by: Logo
Seminar Presentation Part of: YIA posters session Pharmacotherapy Delegate Premium access HFA Winter Research Meeting 2026 Heart Failure Association (HFA)

14 More presentations in this session

Presentation thumbnail
Class IIa HDACs Inhibition reverses diastolic dysfunction and Increase Energy Expenditure in a murine HFpEF model
Abstract Slides
Presentation thumbnail
BET proteins link epigenetic remodeling to impaired autophagy in HFpEF
Abstract Slides
Presentation thumbnail
SDF-1/CXCR4 signaling promotes atrial fibrillation in heart failure with preserved ejection fraction
Abstract Slides
Presentation thumbnail
Cardiac metabolic alterations as a novel therapeutic target in doxorubicin toxicity
Abstract Slides
Presentation thumbnail
Unexpected concentric cardiac remodeling induced by selective in vivo cleavage of titin springs in a genetic mouse model.
Abstract Slides

Access the full session

Session thumbnail
YIA posters session

The Event

Event poster

HFA Winter Research Meeting 2026

26 January 2026 17:30 CET
You may be interested in
thumbnail
Congress Presentation
Myocardial ketone body oxidation underlies the salutary effects of SGLT2 inhibitor treatment in heart failure
21 May 2023
thumbnail
Congress Session
Advances in medical therapy in heart failure
20 May 2025
thumbnail
Congress Session
Young Investigator Award (YIA) Basic Science
17 May 2025
thumbnail
Congress Presentation
Empagliflozin promotes reverse remodeling via cardiometabolic reprogramming in established pressure-overload left ventricular hypertrophy
30 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources